Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 601–700 of 736
Nanomedical drug delivery for neurodegenerative disease
Kaur, N., Kumar, V., Mahender, T., Maji, I., Mahajan, S., Aalhate, M., Singh, P. K., & Sahu, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00016-2 · Cited by 3
Mueller, K. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-45190-4_4 · Cited by 5
Doering, S., McKay, N. S., Jana, N., Dombrowski, K., McCullough, A. A., Millar, P. R., Hobbs, D. A., Agrawal, R., Flores, S. E., Llibre‐Guerra, J. J., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00405 · Cited by 5
“Previous histopathological studies demonstrated a progressive spatial pattern of tau in AD (Braak & Braak, 1991) beginning in the entorhinal cortex, expanding to the medial temporal lobe, and finally reaching additional neocortical regions (Gordon et al., 2016; Takeda, 2019).”
Self-citationIn search of Alzheimer’s disease treatment methods: trends of clinical trials
Pakulaite-Kazliene, G., Regelskytė, V., Audronytė, E., Kuzmickienė, J., & Kaubrys, G. (2018) · Neurologijos seminarai · doi:10.29014/ns.2018.03 · Cited by 1
Neural tissue microphysiological systems in the era of patient-derived pluripotent stem cells
Mungenast, A. E., Aron, R., White, J. D., Tardiff, D. F., & Raja, W. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00009-8 · Cited by 3
When wrong answers lead us down the right path
Thomas, K. R., & Au, R. (2021) · International Psychogeriatrics · doi:10.1017/s1041610221002581 · Cited by 2
Diagnose It Yourself: Will There Be a Home Test Kit for Alzheimer’s disease?
Menne, F., & Schipke, C. G. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0065 · Cited by 3
F-18 ML-104 tau PET imaging in mild cognitive impairment
Jaleel, J., Tripathi, M., Baghel, V., Arunraj, S. T., Kumar, P., Khan, D., Tripathi, M., Dey, A. B., & Bal, C. (2021) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001415 · Cited by 2
Alzheimer's disease: Newer biomarkers
Dangi, A., Chatterjee, K., Banwa, M. S., Chauhan, V. S., & Yadav, P. (2021) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.328840 · Cited by 2
“[31] Some researchers have found that compared to amyloid-beta deposits temporal lobe tau deposition was a better predictor of cognitive decline.[32]”
BackgroundLima, M., Tábuas‐Pereira, M., Durães, J., Vieira, D., Faustino, P., Baldeiras, I., & Santana, I. J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220897 · Cited by 2
PET Imaging Agents for Alzheimer’s Disease
Choi, S., Plöessl, K., Zhu, L., & Kung, H. F. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_18 · Cited by 4
Tau pathology in early Alzheimer’s disease disrupts selective neurophysiological network dynamicsPreprint
Kocagöncü, E., Quinn, A. J., Firouzian, A., Cooper, E., Greve, A., Gunn, R. N., Green, G. G. R., Woolrich, M. W., Henson, R. N., Lovestone, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/524355 · Cited by 2
“This ligand binds to Tau aggregates in Alzheimer’s disease, in proportion to disease severity (Brier et al., 2016; Passamonti et al., 2017), and mirrors the distribution of pathology and functional deficits in variant presentations of Alzheimer’s disease (Ossenkoppele et al.”
BackgroundA mechanistic model explains oscillatory slowing and neuronal hyperactivity in Alzheimer’s diseasePreprint
Alexandersen, C. G., de Haan, W., Bick, C., & Goriely, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.20.496731 · Cited by 2
“Although the presence of Aβ is the most reliable diagnostic criteria for AD [15], it is the spreading of pathological τP that shows the highest correlation with brain atrophy [16] and cognitive decline [8, 17] leading to the clinical stage of the disease [18, 19].”
BackgroundRamsden, C. E., Zamora, D., Horowitz, M. S., Jahanipour, J., Keyes, G. S., Li, X., Murray, H. C., Curtis, M. A., Faull, R. L. M., Sedlock, A. B., et al. (2023) · medRxiv · doi:10.21203/rs.3.rs-2968020/v1 · Cited by 2
Factors associated with age at tau pathology onset and time from tau onset to dementiaPreprint
Heston, M. B., Teague, J. P., Cody, K. A., Deming, Y. K., Chavez, E. R. D., Morse, J., Chin, N. A., Engelman, C. D., Chappell, R. J., Langhough, R. E., et al. (2025) · medRxiv · doi:10.1101/2025.03.11.25323773 · Cited by 2
“These findings agree with previous work suggesting the combination of amyloid and tau are strong predictors of preclinical cognitive decline and dementia[7,47,48].”
Cyclic E2 and P4 on Alzheimer’s Disease Pathways
Wiley, T. S., & Haraldsen, J. T. (2017) · Advances in Alzheimer s Disease · doi:10.4236/aad.2017.61003 · Cited by 2
Biomarkers for Alzheimer's Disease: Early Diagnosis
Panwar, D., Sharma, P., Sharma, S., Malik, M., & Kaur, J. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch003 · Cited by 1
Xu, X., Mo, X., Zhang, W., Liu, D., Chen, Q., Lu, J., Zhu, Y., Chen, J., Zhang, X., Zhu, Z., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322539 · Cited by 1
The role of nuclear medicine in central nervous system evaluation
Shadmani, G., Swingle, C. A., & Coffman, C. H. (2025) · The Neuroradiology Journal · doi:10.1177/19714009251345100 · Cited by 1
“37 A positive scan reveals heightened neocortical activity in the posterolateral temporal, occipital, or parietal/ precuneus regions, potentially extending to the frontal areas.”
Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease
Yim, S., Gu, Y., Kang, H., Shin, D., Jang, H., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006088 · Cited by 2
Foukarakis, I., Androni, X., Sampatakakis, S. N., Mamalaki, E., Ntanasi, E., Yannakoulia, M., Chatzipanagiotou, S., Papandreou, C., Kyrozis, A., Tsapanou, A., et al. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.108691 · Cited by 2
Fully individualized models for cross-sectional and longitudinal network-based tau spread
Brown, C., Das, S. R., Detre, J. A., Nasrallah, I. M., Yushkevich, P. A., McMillan, C. T., & Wolk, D. A. (2025) · Imaging Neuroscience · doi:10.1162/imag.a.1053 · Cited by 4
“…Braak staging with tau pathology starting in the transentorhinal cortex and hippocampus prior to spreading to additional limbic and temporal neocortical regions and then to parietal, frontal, and occipital cortex ( Braak & Braak, 1991; Brier et al., 2016; Klunk et al., 2004; Schwarz et al., 2016).”
Lu, H., Yang, C.-Y., Zhang, H., Shi, X., Huang, P., Liu, P.-K., Wang, Z., Asthana, S., Carlsson, C. M., Okonkwo, O. C., et al. (2026) · ACS Central Science · doi:10.1021/acscentsci.5c02048 · Cited by 1
Rani, N., Moghekar, A., Callow, D. D., Alm, K. H., Pettigrew, C. A., Soldan, A., Miller, M. H., Wang, J., Lodge, M. A., Albert, M., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214620 · Cited by 1
Ren, D., Chai, X., Chenyao, X., Zhao, Y., Sun, P., Wang, M., Li, J., Wu, J., Yi, C., Chen, S., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1757330 · Cited by 2
Karim, F., Biju, A. P., Liang, C., Santos, C. J., Rajarethenam, M., & Mukherjee, J. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02267-1 · Cited by 4
“The deposition of tau closely parallels the severity of cognitive decline in AD more than Aβ plaque, emphasizing tau mechanisms to track disease progression [9, 55].”
Szabó, A., Farkas, S., Kádár, A., Török, B., Fazekas, C. L., Sipos, E., Bánrévi, K., Correia, P., Chaves, T., Kovács, T., et al. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107839 · Cited by 1
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies
Yanagisawa, D., Ohgita, T., Kawashima, H., Yoshikawa, H., Saito, H., Tooyama, I., & Takata, K. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109084 · Cited by 1
Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.003 · Cited by 1
Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain
Pissarek, M. (2017) · World Journal of Neuroscience · doi:10.4236/wjns.2017.71010 · Cited by 1
Featured Article Alzheimer's drug-development pipeline: 2016
Cummings, J. L., Morstorf, T., & Lee, G. (2016) · Cited by 1
Fließbach, K., & Schneider, A. (2018) · Der Nervenarzt · Cited by 1
Time-Resolved In Situ AFM Measurement of Growth Rates of Aβ40 Fibrils
Vekilov, P. G., & Wolynes, P. G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2597-2_6 · Cited by 2
An Experimental Study on Evaluating Alzheimer’s Disease Features using Data Mining Techniques
Albalawi, H. (2022) · Journal of Information & Knowledge Management · doi:10.1142/s0219649222500782 · Cited by 1
Traits and Trammels of Tau Tracer Imaging
Villemagne, V. L., Lopresti, B. J., Doré, V., Minhas, D. S., Gogola, A., Nadkarni, N. K., Mason, N. S., Bourgeat, P., López, O. L., Ikonomović, M. D., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_6 · Cited by 1
The role of human serum albumin in prevention and treatment of Alzheimer’s disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2023) · Журнал общей биологии · doi:10.31857/s0044459623020069 · Cited by 1
Convergence of Accelerated Brain Volume Decline in Normal Aging and Alzheimer’s Disease Pathology
Avelar‐Pereira, B., Phillips, C. M., Hosseini, S. M. H., & Initiative, A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231458 · Cited by 1
Petersen, K. K., Nallapu, B. T., Lipton, R. B., Grober, E. H., Davatzikos, C. A., Harvey, D. J., Nasrallah, I. M., Ezzati, A., Initiative, A. D. N., Petersen, K. K., et al. (2025) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaf085 · Cited by 1
Alzheimer’s Disease: What Do We Know About It and How Can We Tackle It?
Mirpuri, B. (2022) · International journal of high school research · doi:10.36838/v4i2.13
de Natale, E. R., Wilson, H., Udeh‐Momoh, C. T., Ford, J. K., Politis, M., & Middleton, L. T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00022-7 · Cited by 2
Possíveis mecanismos fisiopatológicos da doença de Alzheimer: revisão de literatura
Jaques, U., de Toledo, L. F., Medeiros, D. E. M., de Oliveira, M. F., & Barreto, L. B. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n2-177 · Cited by 7
Abnormal CD8 T cells induce and track Alzheimer’s-like neurodegenerationPreprint
Wheeler, C. J., Panwar, A., Rentsendorj, A., Jhun, M., Cohen, R., Cordner, R., Gull, N., Pechnick, R. N., Duvall, G., Mardiros, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-199647/v1 · Cited by 2
Faculty Opinions recommendation of Tau kinetics in neurons and the human central nervous system.
Millan, M. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732876856.793545483 · Cited by 1
Gebre, R. K., Moscoso, A., Raghavan, S. K., Wiste, H. J., Sparrman, K. J., Heeman, F., Costoya‐Sánchez, A., Schwarz, C. G., Spychalla, A. J., Lowe, V. J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3290598/v1 · Cited by 1
ERP-based Detection of Brain Pathology in Rat Models for Preclinical Alzheimer's Disease
Nouriziabari, S. B. (2016) · TSpace (University of Toronto)
Membrane characteristics and vascular cognitive impairment
Zhitkova, Y. V., Khasanova, D. R., & OSLOPOV, V. N. (2017) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2017-4-10-16
“Revealing of impaired Tau-protein metabolism is the most diagnostically valuable approach as it mostly correlates with alterations in various cognitive spheres [21,22].”
BackgroundTargeting Astrocytes With Viral Gene Therapy for Alzheimer’s Disease
Rosenthal, Z. P., Kraft, A. W., Czerniewski, L. R., & Lee, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00005-3 · Cited by 1
Bos, I., Vos, S. J. B., Verhey, F. R. J., & Visser, P. J. (2019) · Neuropraxis · doi:10.1007/s12474-019-00215-5
Han, C., Rundo, L., Murao, K., Milacski, Z. Á., Umemoto, K., Sala, E., Nakayama, H., & Satoh, S. (2019) · arXiv (Cornell University) · doi:10.17863/cam.72542
Sanchez, J. J. (2019) · UNM’s Digital Repository (University of New Mexico)
PET Biomarkers for Tau Pathology
Leuzy, A., Heurling, K., & Schöll, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27779-6_13
Spatial Navigation Ability as a Predictor of Increased Clinical Impairment
Hindershott, T. (2019) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/mz46-3168
Vascular and Degenerative Dementia Convergences More Than Differences
Rodríguez‐Leyva, I. (2020) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2020.06.000641 · Cited by 1
Jastrzębski, K. (2016) · Aktualności Neurologiczne
Limitations of amyloid imaging in Alzheimer's disease
Weidman, D. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00031-1
A novel equilibrative nucleoside transporter 1 inhibitor alleviates Tau-mediated neurodegenerationPreprint
Chang, C., Chang, Y., Chuang, P., Nguyen, T. N. A., Chou, F.-Y., Cheng, S., Chen, H., Jin, L., Carvalho, K., Huin, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.25.334201
“The latter is particularly known to be associated with neuritic dystrophy, synapse loss, and neuroinflammation, which lead to cognitive impairments (Ittner and Gotz, 2011; Brier et al., 2016; Laurent et al., 2018; Colin et al., 2020).”
BackgroundMisiura, M. B. (2020) · Digital Archive @ GSU · doi:10.57709/20304573
CERAMIDE-ENRICHED EXTRACELLULAR VESICLES
Elsherbini, A. M. (2020) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2020.474
Modelling prognostic trajectories in Alzheimer’s disease
Giorgio, J. (2020) · Apollo (University of Cambridge) · doi:10.17863/cam.58841
CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer DiseasePreprint
Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E. W., Christian, B. T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3746265
Self-citationImaging of FTLD-tau Using [18F]AV-1451
Burke, C. (2017) · TSpace (University of Toronto)
The Longitudinal Relationships between Biomarkers of Alzheimer’s Disease
Krance, S. H. (2019) · TSpace (University of Toronto)
Tau Imaging in Neurodegenerative Dementia
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_12
Self-citationЯхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES · Cited by 1
Interview with Farid Khan, PhD
(2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.29051.fkh
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Cahan, J. G., Vassar, R. J., & Bonakdarpour, B. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220064
“Based on the link between tau deposition, clinical symptoms, and structural changes in the brain [10, 11, 14], along with widespread reports of normal cognition in the setting of amyloid deposition [11, 15, 16], we hypothesized that elevated Tau would predict sooner time to antipsychotic use.”
BackgroundChen, X., Liang, S., Lin, B., Weilin, L. I. U., & Huang, J. (2023) · Rehabilitation Medicine · doi:10.3724/sp.j.1329.2023.02007
Spatial association between distributed β-amyloid and tau varies with cognitionPreprint
Carbonell, F., McNicoll, C., Zijdenbos, A. P., Bedell, B. J., & Initiative, A. D. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.559737
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12486836
Self-citationCortical Tau Aggregation Patterns associated with Apraxia in Alzheimer‘s DiseasePreprint
Bischof, G. N., Jaeger, E., Giehl, K., Jessen, F., Onur, O. A., O’Bryant, S. E., Kara, E., Weiss, P. H., & Drzezga, A. E. (2024) · medRxiv · doi:10.1101/2024.04.09.24305535
FPDGL: Functional-Pathological Dual Graph Learning for Alzheimer’s Disease Diagnosis
Xu, J., Kang, K., Chen, J., An, S., Tang, R., & Liu, P. (2024) · International Conference on Intelligent Perception and Computer Vision (CIPCV) · doi:10.1109/cipcv61763.2024.00031
PET Biomarkers for Tau Pathology
Leuzy, A., Heurling, K., & Schöll, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-54196-4_13
Xiong, C., Lu, R., Bui, Q. V. P., Popp, B., Schindler, S. E., Shriver, L. P., Cruchaga, C., Hassenstab, J. J., Benzinger, T. L. S., Agboola, F., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5118913/v1
Self-citationGirija, K. R., Elayaperumal, L., Perinbaraj, S., Krishnamurthy, S., & Gajendra, T. A. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072326297240919095545
Framework for assessing the risk to a field from fraudulent researchPreprint
Ni, C., & Hutchins, B. I. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.630160
New Research on Biomarkers in Alzheimer’s Continuum
Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615 · Cited by 3
The Effect of Resistance and Endurance Exercise on Alzheimer's Biomarkers: A Review Article
Tabibvand, P., Asadollahi, S., & Dadkhah, M. (2024) · مجله دانشگاه علوم پزشکی اردبیل · doi:10.61186/jarums.24.3.241
Nonamyloid-beta active immunization for the treatment of Alzheimer’s disease
Triplett, O., Varda, N., Decourt, B., & Sabbagh, M. N. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2551352
“Together, these features highlight the promise of tau-targeted vaccines as a potentially sustainable and disease-modifying approach to AD [27–32].”
Regional brain aging patterns reveal disease-specific pathways of neurodegenerationPreprint
Vakli, P., Weiss, B., Keresztes, A., Hermann, P., Initiative, A. D. N., Cole, J. H., & Vidnyánszky, Z. (2025) · medRxiv · doi:10.1101/2025.11.12.25339989 · Cited by 1
“Tau-PET imaging, using the [18F]flortaucipir (FTP) tracer, has shown high accuracy in differentiating AD from other tauopathies 46 and can be used to predict cognitive performance 47 and subsequent brain atrophy 48 in AD.”
Shu, Y., Li, Z., Li, Z., Feng, W., & Li, W. (2025) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2025.100514
Bitar, G. A., Alban, S., Beyene, K. M., Decourt, B., Harirchian, S., & Sabbagh, M. N. (2025) · Research Square · doi:10.21203/rs.3.rs-8168314/v1
Putative Survival Advantages in Infant, Child, and Young Adult Apolipoprotein ε4 Carriers
Smith, C. J., Ashford, J. W., & Perfetti, T. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_13-1
Seo, E. H., Lim, H. J., Yoon, H.-J., Choi, K. Y., Lee, J. J., Park, J. Y., Choi, S. H., Kim, H., Kim, B. C., & Lee, K. H. (2021) · Figshare · doi:10.6084/m9.figshare.16779366
Xia, F., Ha, Y., Shi, S., Li, Y., li, S., Luisi, J. D., Kayed, R., Motamedi, M., Liu, H., & Zhang, W. (2021) · Figshare · doi:10.6084/m9.figshare.14302635
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192098
Horie, K., Barthélemy, N. R., Mallipeddi, N., Li, Y., Franklin, E. E., Perrin, R. J., Bateman, R. J., & Sato, C. (2020) · Figshare · doi:10.6084/m9.figshare.12886049
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12872198
Self-citationRégy, M., Dugravot, A., Sabia, S., Bouaziz-Amar, É., Paquet, C., Hanseeuw, B. J., Singh‐Manoux, A., & Dumurgier, J. (2023) · Figshare · doi:10.6084/m9.figshare.22624720
Biel, D., Brendel, M., Rubinski, A., Büerger, K., Janowitz, D., Dichgans, M., & Franzmeier, N. (2021) · Figshare · doi:10.6084/m9.figshare.15162146
Chong, C.-M., Tan, Y., Tong, J., Ke, M., Zhang, K., Yan, L., Cen, X., Lu, J., Chen, G., Su, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488689
Gallagher, R. L., Koscik, R. L., Moody, J. F., Vogt, N. M., Adluru, N., Kecskemeti, S., Van Hulle, C. A., Chin, N. A., Asthana, S., Kollmorgen, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26628052
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192104
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192095
Chang, C.-P., Chang, Y.-G., Chuang, P.-Y., Nguyen, T. N. A., Wu, K.-C., Chou, F.-Y., Cheng, S.-J., Chen, H.-M., Jin, L.-W., Carvalho, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14826218
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192101
Karim, F., Biju, A. P., Liang, C., Santos, C. J., Rajarethenam, M., & Mukherjee, J. (2026) · Research Square · doi:10.21203/rs.3.rs-8463304/v1
Satoh, R., Ali, F., Dickson, D. W., Lowe, V. J., Josephs, K. A., & Whitwell, J. L. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271019 · Cited by 1
Rice, M., Willoughby-Dudley, K. A., Lin, M., Wang, H., Davalos, D. B., & Initiative, A. D. N. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424407
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.